Exelixis, Inc. $EXEL Shares Sold by Retirement Systems of Alabama

Retirement Systems of Alabama trimmed its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL) by 12.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 713,068 shares of the biotechnology company’s stock after selling 97,587 shares during the period. Retirement Systems of Alabama owned about 0.29% of Exelixis worth $41,650,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in EXEL. BlackRock Inc. bought a new stake in shares of Exelixis in the 2nd quarter valued at about $1,581,991,000. Dimensional Fund Advisors LP boosted its stake in shares of Exelixis by 0.9% during the first quarter. Dimensional Fund Advisors LP now owns 4,299,597 shares of the biotechnology company’s stock valued at $184,391,000 after purchasing an additional 39,920 shares in the last quarter. Assetmark Inc. boosted its stake in shares of Exelixis by 1.7% during the first quarter. Assetmark Inc. now owns 3,388,920 shares of the biotechnology company’s stock valued at $145,351,000 after purchasing an additional 58,149 shares in the last quarter. First Trust Advisors LP boosted its stake in shares of Exelixis by 62.0% during the first quarter. First Trust Advisors LP now owns 2,534,992 shares of the biotechnology company’s stock valued at $108,726,000 after purchasing an additional 970,144 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC increased its holdings in Exelixis by 21.5% during the third quarter. Allspring Global Investments Holdings LLC now owns 2,427,976 shares of the biotechnology company’s stock valued at $140,677,000 after buying an additional 429,505 shares during the period. 85.27% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

EXEL has been the topic of several research reports. Royal Bank Of Canada lifted their price objective on shares of Exelixis from $51.00 to $58.00 and gave the company a “sector perform” rating in a report on Friday, October 30th. Stifel Nicolaus upped their target price on Exelixis from $47.00 to $51.00 and gave the stock a “hold” rating in a report on Thursday, August 6th. Wall Street Zen raised Exelixis from a “buy” rating to a “strong-buy” rating in a research report on Monday. Barclays lifted their price target on Exelixis from $49.00 to $54.00 and gave the company an “equal weight” rating in a report on Friday, October 30th. Finally, UBS Group set a $55.00 price target on Exelixis in a research report on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Exelixis presently has an average rating of “Hold” and an average price target of $58.85.

Exelixis Stock Performance

EXEL stock opened at $70.58 on Wednesday. Exelixis, Inc. has a one year low of $39.71 and a one year high of $73.69. The firm has a market cap of $17.22 billion, a price-to-earnings ratio of 21.13, a PEG ratio of 1.85 and a beta of 0.45. The firm has a 50-day simple moving average of $61.59 and a two-hundred day simple moving average of $51.84.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings data on Thursday, October 29th. The biotechnology company reported $0.94 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.89 by $0.05. The firm had revenue of $658.70 million for the quarter, compared to the consensus estimate of $646.51 million. Exelixis had a net margin of 35.45% and a return on equity of 45.54%. The company’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.78 EPS. As a group, equities analysts predict that Exelixis, Inc. will post 3.42 earnings per share for the current fiscal year.

Exelixis Company Profile

Exelixis, Inc. is a biotechnology company focused on discovering, developing and commercializing medicines for cancer. Founded in 1994 and headquartered in Alameda, California, the company has built its business around oncology treatments and continues to advance a pipeline of potential cancer therapies. Its principal marketed medicine is cabozantinib, sold in the United States as Cabometyx and Cometriq. Cabometyx is used to treat certain patients with advanced kidney, liver and thyroid cancers, while Cometriq is used for medullary thyroid cancer.